| Title | Anaplastic lymphoma kinase in human cancer. |
| Publication Type | Journal Article |
| Year of Publication | 2011 |
| Authors | Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, Kwee I, Bertoni F, Piccaluga PPaolo, Pileri SA, Inghirami G |
| Corporate Authors | European T-Cell Lymphoma Study Group |
| Journal | J Mol Endocrinol |
| Volume | 47 |
| Issue | 1 |
| Pagination | R11-23 |
| Date Published | 2011 Aug |
| ISSN | 1479-6813 |
| Keywords | Anaplastic Lymphoma Kinase, Antineoplastic Agents, Crizotinib, CSK Tyrosine-Protein Kinase, Humans, Intracellular Signaling Peptides and Proteins, Lymphoma, Mutation, Neoplasms, Phosphatidylinositol 3-Kinases, Phospholipase C gamma, Piperidines, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Proto-Oncogene Proteins p21(ras), Pyrazoles, Pyridines, Receptor Protein-Tyrosine Kinases, Signal Transduction, src-Family Kinases, Transcriptional Activation, Translocation, Genetic, Up-Regulation |
| Abstract | The receptor tyrosine kinases (RTKs) play a critical role, controlling cell proliferation, survival, and differentiation of normal cells. Their pivotal function has been firmly established in the pathogenesis of many cancers as well. The anaplastic lymphoma kinase (ALK), a transmembrane RTK, originally identified in the nucleophosmin (NPM)-ALK chimera of anaplastic large cell lymphoma, has emerged as a novel tumorigenic player in several human cancers. In this review, we describe the expression of the ALK-RTK, its related fusion proteins, and their molecular mechanisms of activation. Novel tailored strategies are briefly illustrated for the treatment of ALK-positive neoplasms. |
| DOI | 10.1530/JME-11-0004 |
| Alternate Journal | J Mol Endocrinol |
| PubMed ID | 21502284 |
Related Faculty:
Giorgio Inghirami, M.D.